These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 303540)

  • 21. Growth characteristics and therapeutic response of transplantable colon tumors in animals.
    Karaivanova MH; Urumov IJ; Boeva MN
    Neoplasma; 1980; 27(3):253-9. PubMed ID: 7453845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new rat colon cancer cell line metastasizes spontaneously: biologic characteristics and chemotherapeutic response.
    Inoue Y; Kashima Y; Aizawa K; Hatakeyama K
    Jpn J Cancer Res; 1991 Jan; 82(1):90-7. PubMed ID: 1900274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Animal model for small cell carcinoma of the lung. Effect of immunosuppression and sex of mouse on tumor growth in nude athymic mice.
    Pettengill OS; Curphey TJ; Cate CC; Flint CF; Maurer LH; Sorenson GD
    Exp Cell Biol; 1980; 48(4):279-97. PubMed ID: 6249655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon gamma increases the antitumor activity of mitomycin C against human colon cancer cells in vitro and in vivo.
    Ishihara M; Kubota T; Watanabe M; Kawano Y; Narai S; Yasui N; Otani Y; Teramoto T; Kitajima M
    Oncol Rep; 1999; 6(3):621-5. PubMed ID: 10203603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil).
    Tschmelitsch J; Barendswaard E; Williams C; Yao TJ; Cohen AM; Old LJ; Welt S
    Cancer Res; 1997 Jun; 57(11):2181-6. PubMed ID: 9187118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy.
    Grassilli E; Narloch R; Federzoni E; Ianzano L; Pisano F; Giovannoni R; Romano G; Masiero L; Leone BE; Bonin S; Donada M; Stanta G; Helin K; Lavitrano M
    Clin Cancer Res; 2013 Jul; 19(14):3820-31. PubMed ID: 23729362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal conditions for the growth of malignant human and animal cell populations in immunosuppressed mice.
    Stanbredge EJ; Boulger LR; Franks CR; Garrett JA; Reeson DE; Bishop D; Perkins FT
    Cancer Res; 1975 Aug; 35(8):2203-12. PubMed ID: 1080073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrinβ6-targeted immunoliposomes mediate tumor-specific drug delivery and enhance therapeutic efficacy in colon carcinoma.
    Liang B; Shahbaz M; Wang Y; Gao H; Fang R; Niu Z; Liu S; Wang B; Sun Q; Niu W; Liu E; Wang J; Niu J
    Clin Cancer Res; 2015 Mar; 21(5):1183-95. PubMed ID: 25549721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumourigenicity testing in immunosuppressed mice: advantages and disadvantages.
    Stanbridge EJ; Perkins FT
    Dev Biol Stand; 1976 Dec 13-15; 37():211-7. PubMed ID: 1031686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.
    Rybak SM; Pearson JW; Fogler WE; Volker K; Spence SE; Newton DL; Mikulski SM; Ardelt W; Riggs CW; Kung HF; Longo DL
    J Natl Cancer Inst; 1996 Jun; 88(11):747-53. PubMed ID: 8637029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potentiation of the antitumor action of 5-fluorouracil with 5-ethyl-2'-deoxyuridine in human colorectal tumor xenografts.
    Kopper L; Magyarosy E; Jeney A; Lapis K; Szabolcs A; Otvös L
    Oncology; 1984; 41(3):155-8. PubMed ID: 6328393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming mitomycin C resistance with semisynthetic derivatives.
    Brattain MG; Willson JK; Long BH; Chakrabarty S; Yeoman LC; Stringfellow DA
    Prog Clin Biol Res; 1986; 223():63-79. PubMed ID: 3101070
    [No Abstract]   [Full Text] [Related]  

  • 33. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.
    Breistøl K; Balzarini J; Sandvold ML; Myhren F; Martinsen M; De Clercq E; Fodstad O
    Cancer Res; 1999 Jun; 59(12):2944-9. PubMed ID: 10383159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma.
    Tang XY; Zhu YQ; Tao WH; Wei B; Lin XL
    Postgrad Med J; 2007 May; 83(979):338-43. PubMed ID: 17488865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ
    Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination chemotherapy in vitro. IV. Response of human colon carcinoma cells to combinations using cis-diamminedichloroplatinum.
    Bergerat JP; Green C; Drewinko B
    Cancer Biochem Biophys; 1979; 3(4):173-80. PubMed ID: 575983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma.
    Badn W; Kalliomäki S; Widegren B; Sjögren HO
    Clin Cancer Res; 2006 Aug; 12(15):4714-9. PubMed ID: 16899622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.